
|Articles|December 1, 2001
No Benefit to Low-Grade Lymphoma Subgroups
MUNICH - While primary cutaneous B-cell lymphomas must be clearly separated from non-Hodgkin's B-cell lymphomas with secondary cutaneous involvement and from cutaneous B-cell pseudolymphomas, "from the truly clinical and prognostic point of view, low-grade lymphomas are one disease," according to Nicola Pimpinelli, M.D., at the annual meeting of the European Academy of Dermatology and Venereology.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension
2
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
3
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
4
Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine
5











